secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2024-07-24T23:59:59+00:00
Accession:  0001683168-24-005049
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharmaceuticals regains Nasdaq minimum bid price compliance after reverse split
--------------------------------------------------------------------------------

- Received Nasdaq notice on July 19, 2024, confirming compliance with Listing Rule 5550(a)(2).
- Compliance achieved after 1-for-9 reverse stock split effective July 5, 2024.
- Company continues trading on Nasdaq Capital Market; delisting risk removed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824005049/0001683168-24-005049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824005049/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-005049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer